Global Molecular Oncology 麻豆原创 Research Report 2024

Publication ID:

PB510240359

Publication Date:

October 24, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Molecular diagnostics in cancer is becoming more and more common in clinical laboratories. Targeted therapy possibilities for malignancies such as multiple myeloma, lymphoma, melanoma, lung, breast, ovarian, prostate, and others are now being assessed using molecular oncology assays.Molecular oncology researchers use a variety of methods, including as in-vitro and in vivo functional models, computational biology, genomics, and tumor imaging, to comprehend biological and clinical characteristics.The genes that produce these proteins may be used as targets in the development of novel anti-cancer medications, chemotherapeutic medicines, or imaging scans. These combinatorial methods are used in molecular oncology to confirm the involvement of novel candidate genes in the genesis of cancer.
The global Molecular Oncology market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Molecular Oncology is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Molecular Oncology is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Molecular Oncology in Hospitals and Clinics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Molecular Oncology include Roche Diagnostics, Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Molecular Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Oncology.
The Molecular Oncology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Molecular Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Molecular Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Roche Diagnostics
Thermo Fisher Scientific Inc.
Illumina, Inc.
Qiagen N.V.
Agilent Technologies, Inc.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
Genomic Health, Inc.
Segment by Type
PCR
NGS (Next Generation Sequencing)
Microarray
FISH (Fluorescent in situ-hybridization)
Others
Segment by Application
Hospitals and Clinics
Diagnostic Laboratories
Cancer Centers and Specialty Clinics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Molecular Oncology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Molecular Oncology 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 PCR
1.2.3 NGS (Next Generation Sequencing)
1.2.4 Microarray
1.2.5 FISH (Fluorescent in situ-hybridization)
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Molecular Oncology 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals and Clinics
1.3.3 Diagnostic Laboratories
1.3.4 Cancer Centers and Specialty Clinics
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Molecular Oncology 麻豆原创 Perspective (2019-2030)
2.2 Global Molecular Oncology Growth Trends by Region
2.2.1 Global Molecular Oncology 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Molecular Oncology Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Molecular Oncology Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Molecular Oncology 麻豆原创 Dynamics
2.3.1 Molecular Oncology Industry Trends
2.3.2 Molecular Oncology 麻豆原创 Drivers
2.3.3 Molecular Oncology 麻豆原创 Challenges
2.3.4 Molecular Oncology 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Oncology Players by Revenue
3.1.1 Global Top Molecular Oncology Players by Revenue (2019-2024)
3.1.2 Global Molecular Oncology Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Molecular Oncology 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Molecular Oncology Revenue
3.4 Global Molecular Oncology 麻豆原创 Concentration Ratio
3.4.1 Global Molecular Oncology 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Oncology Revenue in 2023
3.5 Global Key Players of Molecular Oncology Head office and Area Served
3.6 Global Key Players of Molecular Oncology, Product and Application
3.7 Global Key Players of Molecular Oncology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Oncology Breakdown Data by Type
4.1 Global Molecular Oncology Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Molecular Oncology Forecasted 麻豆原创 Size by Type (2025-2030)
5 Molecular Oncology Breakdown Data by Application
5.1 Global Molecular Oncology Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Molecular Oncology Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Molecular Oncology 麻豆原创 Size (2019-2030)
6.2 North America Molecular Oncology 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Molecular Oncology 麻豆原创 Size by Country (2019-2024)
6.4 North America Molecular Oncology 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Molecular Oncology 麻豆原创 Size (2019-2030)
7.2 Europe Molecular Oncology 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Molecular Oncology 麻豆原创 Size by Country (2019-2024)
7.4 Europe Molecular Oncology 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Oncology 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Molecular Oncology 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Molecular Oncology 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Molecular Oncology 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Molecular Oncology 麻豆原创 Size (2019-2030)
9.2 Latin America Molecular Oncology 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Molecular Oncology 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Molecular Oncology 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Oncology 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Molecular Oncology 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Molecular Oncology 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Molecular Oncology 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche Diagnostics
11.1.1 Roche Diagnostics Company Details
11.1.2 Roche Diagnostics Business Overview
11.1.3 Roche Diagnostics Molecular Oncology Introduction
11.1.4 Roche Diagnostics Revenue in Molecular Oncology Business (2019-2024)
11.1.5 Roche Diagnostics Recent Development
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Details
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Molecular Oncology Introduction
11.2.4 Thermo Fisher Scientific Inc. Revenue in Molecular Oncology Business (2019-2024)
11.2.5 Thermo Fisher Scientific Inc. Recent Development
11.3 Illumina, Inc.
11.3.1 Illumina, Inc. Company Details
11.3.2 Illumina, Inc. Business Overview
11.3.3 Illumina, Inc. Molecular Oncology Introduction
11.3.4 Illumina, Inc. Revenue in Molecular Oncology Business (2019-2024)
11.3.5 Illumina, Inc. Recent Development
11.4 Qiagen N.V.
11.4.1 Qiagen N.V. Company Details
11.4.2 Qiagen N.V. Business Overview
11.4.3 Qiagen N.V. Molecular Oncology Introduction
11.4.4 Qiagen N.V. Revenue in Molecular Oncology Business (2019-2024)
11.4.5 Qiagen N.V. Recent Development
11.5 Agilent Technologies, Inc.
11.5.1 Agilent Technologies, Inc. Company Details
11.5.2 Agilent Technologies, Inc. Business Overview
11.5.3 Agilent Technologies, Inc. Molecular Oncology Introduction
11.5.4 Agilent Technologies, Inc. Revenue in Molecular Oncology Business (2019-2024)
11.5.5 Agilent Technologies, Inc. Recent Development
11.6 Abbott Laboratories
11.6.1 Abbott Laboratories Company Details
11.6.2 Abbott Laboratories Business Overview
11.6.3 Abbott Laboratories Molecular Oncology Introduction
11.6.4 Abbott Laboratories Revenue in Molecular Oncology Business (2019-2024)
11.6.5 Abbott Laboratories Recent Development
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Bio-Rad Laboratories, Inc. Company Details
11.7.2 Bio-Rad Laboratories, Inc. Business Overview
11.7.3 Bio-Rad Laboratories, Inc. Molecular Oncology Introduction
11.7.4 Bio-Rad Laboratories, Inc. Revenue in Molecular Oncology Business (2019-2024)
11.7.5 Bio-Rad Laboratories, Inc. Recent Development
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Company Details
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Molecular Oncology Introduction
11.8.4 Myriad Genetics, Inc. Revenue in Molecular Oncology Business (2019-2024)
11.8.5 Myriad Genetics, Inc. Recent Development
11.9 Genomic Health, Inc.
11.9.1 Genomic Health, Inc. Company Details
11.9.2 Genomic Health, Inc. Business Overview
11.9.3 Genomic Health, Inc. Molecular Oncology Introduction
11.9.4 Genomic Health, Inc. Revenue in Molecular Oncology Business (2019-2024)
11.9.5 Genomic Health, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Roche Diagnostics
Thermo Fisher Scientific Inc.
Illumina, Inc.
Qiagen N.V.
Agilent Technologies, Inc.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
Genomic Health, Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.